# UZ Leuven / Leuven Cancer Institute

Source: https://onco.cc/institutions/uz-leuven/  
OnCo record `uz-leuven` (Institution). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Belgium's largest university hospital and an OECI-accredited comprehensive cancer centre, with world-class gastrointestinal, gynaecological and angiogenesis research.

## Summary

The Leuven Cancer Institute coordinates cancer care and research across UZ Leuven and KU Leuven and holds OECI comprehensive cancer centre status. Eric Van Cutsem's gastrointestinal group led the CRYSTAL and other trials that defined anti-EGFR therapy in RAS wild-type colorectal cancer, Ignace Vergote shaped surgical and medical management of ovarian cancer through EORTC and ENGOT trials, and Frédéric Amant founded the international network on cancer during pregnancy. The VIB-KU Leuven Center for Cancer Biology (Peter Carmeliet, Diether Lambrechts, Jean-Christophe Marine) is a leading site for angiogenesis, tumour genomics and melanoma research, and Hans Wildiers is a reference in geriatric oncology. The ParTICLe proton therapy centre opened on the Gasthuisberg campus in 2020.

## Fields

- Kind: Institution
- Last checked: 2026-09-09
- Also known as: Leuvens Kankerinstituut; LKI; University Hospitals Leuven
- City: Leuven, BE
- Type: cancer-center
- Website: https://www.uzleuven.be

## Sources

- Leuven Cancer Institute: https://www.uzleuven.be
- VIB-KU Leuven Center for Cancer Biology: https://cancerbiology.sites.vib.be
- PTCOG: particle therapy facilities in operation: https://www.ptcog.site/index.php/facilities-in-operation-public

## Connected records

- cancers: [Cervical cancer](https://onco.cc/cancers/cervical/), [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Melanoma](https://onco.cc/cancers/melanoma/), [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- fronts: [Radiation Therapy](https://onco.cc/fronts/radiation/), [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- technologies: [Anti-angiogenic therapy](https://onco.cc/technologies/antiangiogenic/), [Geriatric assessment](https://onco.cc/technologies/geriatric-assessment/), [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/), [Proton therapy](https://onco.cc/technologies/proton-therapy/), [Proton therapy machines: cyclotrons, synchrotrons and single-room systems](https://onco.cc/technologies/proton-therapy-systems/)
- targets: [EGFR](https://onco.cc/targets/egfr/), [VEGF / VEGFR](https://onco.cc/targets/vegf/)
- companies: [EORTC](https://onco.cc/companies/curie-nki-eortc/), [IBA (Ion Beam Applications)](https://onco.cc/companies/iba/)
- institutions: [AZ Groeninge Kortrijk Cancer Centre](https://onco.cc/institutions/az-groeninge-kortrijk/), [Ghent University Hospital / Cancer Research Institute Ghent](https://onco.cc/institutions/uz-gent/), [Organisation of European Cancer Institutes](https://onco.cc/institutions/oeci/)
- people: [Eric Van Cutsem](https://onco.cc/people/eric-van-cutsem/), [Ignace Vergote](https://onco.cc/people/ignace-vergote/), [Patrick Schöffski](https://onco.cc/people/patrick-schoffski/), [Paul Herijgers](https://onco.cc/people/paul-herijgers/)

---
JSON: https://onco.cc/api/v1/entities/uz-leuven.json